S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:TPTX

Turning Point Therapeutics Stock Forecast, Price & News

$103.09
-8.59 (-7.69 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$101.37
Now: $103.09
$112.10
50-Day Range
$111.68
MA: $127.48
$140.01
52-Week Range
$31.30
Now: $103.09
$141.30
Volume465,262 shs
Average Volume266,413 shs
Market Capitalization$4.97 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.23
Turning Point Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+, or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and TPX-0131, a preclinical ALK inhibitor. The company was founded in 2013 and is headquartered in San Diego, California.
Turning Point Therapeutics logo

Headlines

Turning Point and Zai Lab Broaden Collaboration
January 11, 2021 |  finance.yahoo.com
Benzinga's Top Upgrades, Downgrades For December 8, 2020
December 8, 2020 |  finance.yahoo.com
Top 10 Healthcare Stocks for the Future
November 29, 2020 |  finance.yahoo.com
Turning Point Therapeutics Inc.
November 28, 2020 |  wsj.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TPTX
CUSIPN/A
CIKN/A
Phone858-926-5251
Employees130
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$11.28 per share

Profitability

Net Income$-72,130,000.00

Miscellaneous

Market Cap$4.97 billion
Next Earnings Date5/11/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.85 out of 5 stars

Medical Sector

120th out of 1,969 stocks

Pharmaceutical Preparations Industry

50th out of 772 stocks

Analyst Opinion: 4.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$103.09
-8.59 (-7.69 %)
(As of 03/4/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TPTX News and Ratings via Email

Sign-up to receive the latest news and ratings for TPTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Turning Point Therapeutics (NASDAQ:TPTX) Frequently Asked Questions

Is Turning Point Therapeutics a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Turning Point Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Turning Point Therapeutics stock.
View analyst ratings for Turning Point Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Turning Point Therapeutics?

Wall Street analysts have given Turning Point Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Turning Point Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Turning Point Therapeutics' next earnings date?

Turning Point Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 11th 2021.
View our earnings forecast for Turning Point Therapeutics
.

How were Turning Point Therapeutics' earnings last quarter?

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) released its quarterly earnings results on Sunday, February, 28th. The company reported ($1.02) EPS for the quarter, missing analysts' consensus estimates of ($0.94) by $0.08.
View Turning Point Therapeutics' earnings history
.

How has Turning Point Therapeutics' stock price been impacted by Coronavirus?

Turning Point Therapeutics' stock was trading at $40.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TPTX stock has increased by 154.3% and is now trading at $103.09.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for TPTX?

7 equities research analysts have issued 12 month price objectives for Turning Point Therapeutics' shares. Their forecasts range from $127.00 to $190.00. On average, they anticipate Turning Point Therapeutics' stock price to reach $153.57 in the next twelve months. This suggests a possible upside of 49.0% from the stock's current price.
View analysts' price targets for Turning Point Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Turning Point Therapeutics' key executives?

Turning Point Therapeutics' management team includes the following people:
  • Dr. Athena Maria Countouriotis, Pres, CEO & Director (Age 49, Pay $985.01k)
  • Ms. Yi Larson, Exec. VP & CFO (Age 41, Pay $864.41k)
  • Dr. Mohammad Hirmand, Exec. VP & Chief Medical Officer (Age 51, Pay $424.25k)
  • Dr. Siegfried Reich, Exec. VP & Chief Scientific Officer (Age 61)
  • Mr. Ed Gemo, Sr. VP & Chief Information Officer
  • Mr. James S. Mazzola, Sr. VP of Corp. Communication & Investor Relations
  • Ms. Annette C. North, Exec. VP, Gen. Counsel & Company Sec. (Age 55)
  • Mr. Andrew John Partridge, Exec. VP & Chief Commercial Officer (Age 52)
  • Ms. Heather Adams, VP of HR
  • Dr. Jeffrey P. Whitten, Sr. VP of Pre-Clinical Devel.

Who are some of Turning Point Therapeutics' key competitors?

What other stocks do shareholders of Turning Point Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Turning Point Therapeutics investors own include NVIDIA (NVDA), Main Street Capital (MAIN), OPKO Health (OPK), The Boeing (BA), General Motors (GM), AbbVie (ABBV), Gilead Sciences (GILD), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ) and Livongo Health (LVGO).

When did Turning Point Therapeutics IPO?

(TPTX) raised $167 million in an initial public offering on Wednesday, April 17th 2019. The company issued 9,300,000 shares at a price of $18.00 per share. Goldman Sachs, SVB Leerink and Wells Fargo Securities acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Turning Point Therapeutics' stock symbol?

Turning Point Therapeutics trades on the NASDAQ under the ticker symbol "TPTX."

Who are Turning Point Therapeutics' major shareholders?

Turning Point Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (12.90%), BlackRock Inc. (6.55%), Price T Rowe Associates Inc. MD (5.28%), Lord Abbett & CO. LLC (2.74%), Alliancebernstein L.P. (1.96%) and Jennison Associates LLC (1.73%). Company insiders that own Turning Point Therapeutics stock include Annette North, Athena Countouriotis, Brian Lee Baker, Carl L Gordon, Cormorant Asset Management, Lp, Jingrong Jean Cui, Mohammad Hirmand, Simeon George and Yi Larson.
View institutional ownership trends for Turning Point Therapeutics
.

Which major investors are selling Turning Point Therapeutics stock?

TPTX stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., FMR LLC, Renaissance Technologies LLC, Voloridge Investment Management LLC, Matthews International Capital Management LLC, Handelsbanken Fonder AB, Castleark Management LLC, and Aviva PLC. Company insiders that have sold Turning Point Therapeutics company stock in the last year include Annette North, Athena Countouriotis, Brian Lee Baker, Jingrong Jean Cui, Mohammad Hirmand, and Yi Larson.
View insider buying and selling activity for Turning Point Therapeutics
or view top insider-selling stocks.

Which major investors are buying Turning Point Therapeutics stock?

TPTX stock was purchased by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Lord Abbett & CO. LLC, BlackRock Inc., Norges Bank, Credit Suisse AG, Candriam Luxembourg S.C.A., Jennison Associates LLC, and Federated Hermes Inc.. Company insiders that have bought Turning Point Therapeutics stock in the last two years include Athena Countouriotis, Brian Lee Baker, Carl L Gordon, Cormorant Asset Management, Lp, Simeon George, and Yi Larson.
View insider buying and selling activity for Turning Point Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Turning Point Therapeutics?

Shares of TPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Turning Point Therapeutics' stock price today?

One share of TPTX stock can currently be purchased for approximately $103.09.

How much money does Turning Point Therapeutics make?

Turning Point Therapeutics has a market capitalization of $4.97 billion. The company earns $-72,130,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis.

How many employees does Turning Point Therapeutics have?

Turning Point Therapeutics employs 130 workers across the globe.

What is Turning Point Therapeutics' official website?

The official website for Turning Point Therapeutics is www.tptherapeutics.com.

Where are Turning Point Therapeutics' headquarters?

Turning Point Therapeutics is headquartered at 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121.

How can I contact Turning Point Therapeutics?

Turning Point Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The company can be reached via phone at 858-926-5251 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.